SCHEMBL18409573

SCHEMBL18409573

COc1ccccc1-c1nc(Cc2c[nH]c3ccccc23)oc1-c1ccccc1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ RXRA P19793 1/20 0.45
▸ GPR84 Q9NQS5 4/20 0.44
▸ PTPN1 P18031 4/20 0.44
▸ CDK4 P11802 1/20 0.44
▸ CCND1 P24385 1/20 0.44
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ AHR P35869 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ ELANE P08246 1/20 0.42
▸ HTR1A P08908 3/20 0.42
▸ HTR6 P50406 3/20 0.42
▸ DRD2 P14416 2/20 0.42
▸ HTR2A P28223 2/20 0.42
▸ HTR7 P34969 2/20 0.42
▸ IDO1 P14902 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18409330 0.93 PTPN1 (0.46) ALDH1A1RAB9ARXRAGPR84PTPN1
SCHEMBL18409341 0.90 RXRA (0.49) RXRACDK4CCND1MEN1KMT2A
SCHEMBL18409640 0.88 HTR1A (0.47) RXRACDK4CCND1MEN1KMT2A
SCHEMBL18409636 0.84 RXRA (0.48) RXRACDK4CCND1MEN1KMT2A
SCHEMBL18409576 0.81 ALDH1A1 (0.49) ALDH1A1RAB9AGPR84PTPN1MEN1
SCHEMBL20419881 0.81 CDK4 (0.45) RAB9ARXRACDK4CCND1MEN1
SCHEMBL18409334 0.81 GPR84 (0.61) ALDH1A1RAB9ARXRAGPR84PTPN1
SCHEMBL18409578 0.81 ALDH1A1 (0.48) ALDH1A1RAB9AGPR84PTPN1MEN1
SCHEMBL20419778 0.80 HTR1A (0.44) RXRACDK4CCND1MEN1KMT2A
SCHEMBL18409680 0.78 GPR84 (0.63) ALDH1A1RAB9AGPR84PTPN1CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10844051-B2 Substituted oxazoles for the treatment of cancer THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY 2020-11-24 — — US disclosed
US-20180208586-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2018-07-26 — — US disclosed
WO-2017011920-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2017-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180208586-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS VHL, TP53, CD44 ALDH1A1 325/4885RAB9A 3253/4885RXRA 172/4885
US-10844051-B2 Substituted oxazoles for the treatment of cancer OXA1L, PDCD1, MCL1 ALDH1A1 292/4885RAB9A 4268/4885RXRA 1247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback